澳洋健康(002172) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥452,119,969.79, a decrease of 22.27% compared to ¥581,691,001.68 in the same period last year[3] - The net profit attributable to shareholders was ¥18,499,176.25, down 39.82% from ¥30,739,368.29 year-on-year[3] - Basic and diluted earnings per share decreased by 50.00%, from ¥0.04 to ¥0.02[3] - The company reported a net loss of CNY 1,914,023,406.35, an improvement from a net loss of CNY 1,932,522,582.60 in the previous period[14] - The net profit for the current period is 18,855,007.11, a decrease of 39.5% compared to 31,137,825.62 in the previous period[18] - Operating profit for the current period is 23,561,806.87, down 34.4% from 35,955,833.29 in the previous period[18] - Total profit for the current period is 24,196,720.51, a decline of 37.7% compared to 38,810,915.19 in the previous period[18] - The company reported sales revenue of 309,625,785.38, a decrease of 39.2% from 509,722,231.34 in the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities was -¥179,940,705.79, an improvement of 15.13% compared to -¥212,015,808.16 in the previous year[3] - Cash flow from operating activities shows a net outflow of -179,940,705.79, improving from -212,015,808.16 in the previous period[20] - Cash and cash equivalents decreased by 45.95% year-on-year, primarily due to increased restricted cash for acceptance bills[8] - Cash and cash equivalents at the end of the period amounted to CNY 461,455,379.42, a decrease of 11.5% from CNY 521,489,938.85 at the beginning of the period[12] - Cash and cash equivalents at the end of the period amount to 226,341,631.14, down from 418,744,268.63 in the previous period[21] - The company’s total cash inflow from financing activities is 665,407,900.61, slightly down from 671,846,211.49 in the previous period[21] - The company’s total cash outflow from investing activities is 16,332,745.34, compared to 15,788,314.50 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,049,816,701.24, a slight decrease of 0.06% from ¥2,051,047,821.36 at the end of the previous year[3] - Total assets decreased slightly to CNY 2,049,816,701.24 from CNY 2,051,047,821.36, a decline of 0.1%[14] - Total liabilities decreased to CNY 1,915,731,197.13 from CNY 1,935,817,324.36, a reduction of 1.0%[14] - The company's equity attributable to shareholders increased to CNY 153,021,601.65 from CNY 134,522,425.40, an increase of 13.7%[14] - Short-term borrowings decreased to CNY 682,185,039.73 from CNY 704,846,127.84, a decline of 3.2%[13] Operational Metrics - The company reported a 39.26% decrease in cash received from sales of goods and services compared to the previous year[8] - Total operating costs for the current period were CNY 428,104,319.98, down 20.9% from CNY 541,279,571.75 in the previous period[16] - Accounts receivable increased to CNY 319,682,576.81 from CNY 291,583,598.00, reflecting a growth of 9.6%[12] - Inventory rose to CNY 167,097,279.41, up 11.8% from CNY 149,474,811.92[13] - The company experienced a 333.47% increase in financial expenses year-on-year, attributed to reduced interest income from maturing deposits[7] - The company incurred financial expenses of 7,562,338.98, compared to a financial income of -3,239,154.66 in the previous period[18] - The weighted average return on equity was 12.87%, down 15.27% from 28.14% in the same period last year[3] - The number of ordinary shareholders at the end of the reporting period was 53,714[9]